Technologies for Genomic Medicines
New genomic therapies are being developed by Sangamo and others which may address the underlying mistakes in DNA that lead to some genetic diseases.
delivery and manufacturing
We currently use both adeno associated virus (AAV) and mRNA to deliver our therapeutics and continue to develop and refine these platforms as well as our manufacturing processes for therapeutic cell production. Using our molecular biology and AAV expertise we are also developing gene therapy approaches for key indications.
Innovation and excellence are coded in our DNA as our scientists continuously strive to improve our technology and capabilities. Currently, we’re working on next-generation ZFN constructs that are up to 20-fold more active than current constructs. This new and improved ZFN 2.0 platform has the potential to enable the development of more potent genomic therapies for a broad range of monogenic diseases.